A.I. Burnasyan FMBC clinical bulletin. 2026 № 4
New Challenges for Clinicians Against the Background of Entrenched Disunity
in Understanding the Principles of Metabolic Syndrome Formation (Literature Review)
A.V. Yanina1,2, V.A. Godilo-Godlevsky1, S.V. Gornov3, E.V. Reznik1,2
1Pirogov Russian National Research Medical University, Moscow, Russia;
²Savelyeva City Clinical Hospital № 31, Moscow, Russia,
3A.I. Burnasyan Federal Medical Biophysical Center, Moscow, Russia
Contact person: Anna V. Yanina: e-mail: annavasguseva@gmail.com
ABSTRACT
Purpose: To identify novel approaches to the management of patients with metabolic syndrome (MS), to demonstrate the necessity of studying distinct disease phenotypes for the early prediction of future cardiovascular complications, and to highlight the role of chronic inflammation as an additional marker of elevated risk.
Material and methods: An analytical review of contemporary scientific literature (2020–2026) and current clinical practice guidelines was conducted. Data from major cohort studies (Kailuan, REGARDS, Cardiometabolic Center Alliance) were analyzed to evaluate the efficacy of interdisciplinary care models and the utility of high-sensitivity C-reactive protein (hs-CRP) and the C-reactive protein-triglyceride glucose index (CTI) in risk stratification. Consensus documents from the Russian Society of Cardiology (2026) and the American College of Cardiology (2025) were also examined.
Results: The prevalence of MS in the Russian Federation was found to range from 6.9% in individuals aged 25–34 to 45.2% in those aged 55–64. The traditional management model was deemed suboptimal due to the lack of unified protocols and the risk of polypharmacy. Interdisciplinary team-based care (MDT) demonstrated high efficacy, achieving a 7.1% reduction in body weight, a 15.1% decrease in HbA1c levels, and a 45% reduction in hospitalization rates (from 1.1±0.4 to 0.6±0.1). In 2026, hs-CRP was incorporated into the diagnostic criteria for cardio-reno-metabolic syndrome (CRMS) in Russia, though the absence of standardized thresholds limits its clinical application. Elevated hs-CRP levels exceeding 3 mg/L were associated with a two-fold increase in cardiovascular event risk. Phenotyping MS (based on combinations of obesity, hypertension, hyperuricemia, and renal dysfunction) enables the prediction of 10-year cardiovascular risk ranging from 0.9% to 51.6% depending on the CRMS stage. The CTI index has been recognized as a promising biomarker for identifying patients requiring intensified surveillance. The implementation of multidisciplinary models in the United States and Europe confirmed a sustained reduction in all major risk factors (LDL-C, blood pressure, and glucose) over a 4-year follow-up period.
Conclusion: Phenotyping metabolic syndrome provides a framework for predicting individual cardiovascular risk trajectories. “High-risk” phenotypes necessitate the initiation of intensive pharmacotherapy at early disease stages. Alongside standard treatment protocols, the development of effective anti-inflammatory strategies remains a critical priority to mitigate residual cardiovascular risk in these patients.
Keywords: metabolic syndrome, cardio-reno-metabolic syndrome, phenotypes, chronic inflammation, high-sensitivity C-reactive protein, model of medical care
For citation: Yanina AV, Godilo-Godlevsky VA, Gornov SV, Reznik EV. New challenges for clinicians against the background of entrenched disunity in understanding the principles of metabolic syndrome formation (literature review). A.I. Burnasyan Federal Medical Biophysical Center Clinical Bulletin. 2026.4:60-65. (In Russian) DOI: 10.33266/2782-6430-2026-4-60-65
REFERENCES
- Чигирь А.Г. Метаболический синдром: актуальные вопросы диагностики, эпидемиологии и профилактики в мире и в Российской Федерации // Эпидемиология и вакцинопрофилактика. Т.25. №4. С. 95–105 [Chigir’ A.G. Metabolic Syndrome: Current Issues Regarding Diagnosis, Epidemiology, and Prevention Globally and in the Russian Federation. Epidemiologiya i Vaktsinoprofilaktika = Epidemiology and Vaccine Prevention. 2025;25;4:95–105 (In Russ.)]. Doi: 10.31631/2073-30462025-24-4-95-105.
- Шляхто Е.В., Недогода С.В., Бабенко А.Ю. и др. Концепция междисциплинарного согласительного документа по кардио-рено-гепато-метаболическому синдрому // Российский кардиологический журнал. 2025. Т.30. №1S. С:16-22 [Shlyakhto Ye.V., Nedogoda S.V., Babenko A.Yu., et al. Concept of an Interdisciplinary Consensus Document on Cardio-Reno-Hepato-Metabolic Syndrome. Rossiyskiy Kardiologicheskiy Zhurnal = Russian Journal of Cardiology. 2025; 30;1S:16–22 (In Russ.)]. Doi: 10.15829/1560-4071-2025-6533.
- Трушина О.Ю. Кардио-рено-метаболический синдром: междисциплинарный подход // Терапевтический архив. 2025. Т.97. №9. С. 789–792 [Trushina O.Yu. Cardio-Reno-Metabolic Syndrome: an Interdisciplinary Approach. Terapevticheskiy Arkhiv = Therapeutic Archive. 2025;97;9:789–792 (In Russ.)]. Doi: 10.26442/00403660. 2025.09.203346.
- Theodorakis N., Nikolaou M. From Cardiovascular-Kidney-Metabolic Syndrome to Cardiovascular-Renal-Hepatic-Metabolic Syndrome: Proposing an Expanded Framework. Biomolecules. 2025;15;2:213-236. Doi: 10.3390/biom15020213.
- Вильсон Н.И., Беленькая Л.В., Шолохов Л.Ф. и др. Метаболический синдром: эпидемиология, критерии диагностики, расовые особенности // Acta Biomedica Scientifica. 2021. Т.6. №4. С. 180-191 [Vil’son N.I., Belen’kaya L.V., Sholokhov L.F., et al. Metabolic Syndrome: Epidemiology, Diagnostic Criteria, and Racial Characteristics. Acta Biomedica Scientifica. 2021;6;4:180–191 (In Russ.]. Doi: 10.29413/ABS.2021-6.4.16.
- Spindler M.P., Libby P., Ridker P.M. Targeting Inflammation in Atherosclerotic Cardiovascular Disease: Mechanisms and Emerging Therapies. Immunological Reviews. 2026;341;1: e70151. Doi: 10.1111/imr.70151
- Grigoriou K., Karakasis P., Nasoufidou A., et al. SGLT2 Inhibitors in the Management of Cardio-Renal-Metabolic Syndrome: a New Therapeutic Era. Medicina (Kaunas). 2025;61;11:1903. Doi: 10.3390/medicina61111903.
- Arragan Lezama C.A., Jaramillo Ramos J.J., Armas Eguizábal D.A., et al. Cardiovascular-Renal-Hepatic-Metabolic Syndrome: Interlinked Pathophysiology and Integrated Management Approach. Cureus. 2025;17;6:e85813. Doi: 10.7759/cureus.85813.
- Gallo G., Savoia C. New Insights into Endothelial Dysfunction in Cardiometabolic Diseases: Potential Mechanisms and Clinical Implications. International Journal of Molecular Sciences. 2024;25;5:2973. Doi: 10.3390/ijms25052973.
- Alberti K.G., Eckel R.H., Grundy S.M., et al. Harmonizing the Metabolic Syndrome: a Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120;16:1640–1645. Doi: 10.1161/CIRCULATIONAHA.109.192644.
- Chung I., Fricska D.I., Banerjee S., et al. Cardiovascular-Kidney-Metabolic Syndrome: Models of Care. Reviews in Cardiovascular Medicine. 2026;27;7:47862. Doi: 10.31083/RCM47862.
- Neeland I.J., Magwire M.L., Kwun A., et al. Optimizing Care in Cardiovascular-Kidney-Metabolic Syndrome: Registry Data From the Cardiometabolic Center Alliance. Circulation: Population Health Outcomes. 2026;19;7: e012828. Doi: 10.1161/CIRCOUTCOMES.125.012828.
- Liu X., Guo Y., Zhao B., et al. Awareness and Perceptions of Systemic Inflammation in Atherosclerotic Cardiovascular Disease and Chronic Kidney Disease: The SPARK-CVD China Survey. Atherosclerosis Plus. 2026;65:100570. Doi: 10.1016/j.athplu.2026.100570.
- Tian Y., Wang Y., Zhao D., et al. Metabolic Syndrome, High-Sensitivity C-Reactive Protein and the Risk of Heart Failure: the Kailuan Cohort Study. Frontiers in Endocrinology. 2025;16:1544823. Doi: 10.3389/fendo.2025.1544823.
- Annink M., Kraaijenhof J., Beverloo C.Y., et al. Estimating Inflammatory Risk in Atherosclerotic Cardiovascular Disease: Plaque Over Plasma? European Heart Journal Cardiovascular Imaging. 2025;26;3:444–460. Doi: 10.1093/ehjci/jeae314.
- Mehta A., Blumenthal R.S., Gluckman T.J., et al. High-Sensitivity C-Reactive Protein in Atherosclerotic Cardiovascular Disease: To Measure or Not to Measure? US Cardiology. 2025;19:e06. Doi: 10.15420/usc.2024.25.
- Wang Y., Luo J., Tan Z., et al. The C-Reactive Protein-Triglyceride Glucose Index and Incidence of Cardiovascular Disease Among Individuals with Hypertension: a Nationwide Prospective Cohort Study. Endocrinology and Metabolism. 2026;17:Art.2958. Doi: 10.3803/EnM.2026.2958.
- Mensah G.A., et al. Inflammation and Cardiovascular Disease: 2025 ACC Scientific Statement. Journal of the American College of Cardiology. 2026;87;11:1381–1404.
- Ben-Assayag H., Brzezinski R.Y., Berliner S., et al. From Having no Metabolic Abnormality Nor Obesity to Metabolic Impairment in a Cohort of Apparently Healthy Adults. Cardiovascular Diabetology. 2023;22;1:226. Doi: 10.1186/s12933-023-01954-w.
- Popoviciu M.S., Ghitea T.C. Age-Stratified Differences in Cardio-Reno-Metabolic Risk Profiles. Geriatrics. 2026;11;1:18. Doi: 10.3390/geriatrics11010018.
- Palazzuoli A., Mattioli A.V., Fedele F. Current Appraisal and Gaps in Knowledge in Cardio-Kidney Metabolic Syndrome Definition. International Journal of Molecular Sciences. 2026;27;4: 1657. Doi: 10.3390/ijms27041657.
- Essa M., Malik D., Lu Y., et al. Long-Term Cardiovascular Risk with Cardiovascular-Kidney-Metabolic Syndrome in U.S Adults. American Heart Journal Plus. 2026;69:100839. Doi: 10.1016/j.ahjo.2026.100839.
- Mahapatro A., Jala S.R.A., Ghodous S., et al. Systemic Immune-Inflammation Index as a Novel Biomarker for Metabolic Syndrome: a Systematic Review and Meta-Analysis. Medicine (Baltimore). 2026;105;27: e49667. Doi: 10.1097/MD.0000000000049667.
- Mdivnishvili M., Kharebashvili M., Chumburidze V., et al. The Impact of Hyperuricemia on the Progression of Atherosclerotic Cardiovascular Disease. Cureus. 2025;17;10:e94371. Doi: 10.7759/cureus.94371.
- Malik M.M., Ganatra N., Siby R., et al. The Cellular Genesis of Metabolic Syndrome and the Role of Anti-Urate Drugs in Hyperuricemia Patients: A Systematic Review. Cureus. 2024;16;6:e62472. Doi: 10.7759/cureus.62472.
- Das D., Shruthi N.R., Banerjee A., et al. Endothelial Dysfunction, Platelet Hyperactivity, Hypertension, and the Metabolic Syndrome: Molecular Insights and Combating Strategies. Front Nutr. 2023; 8;10:1221438. Doi: 10.3389/fnut.2023.1221438. PMID: 37614749; PMCID: PMC10442661.
- Ruan G.T., Xie H.L., Zhang H.Y., et al. A Novel Inflammation and Insulin Resistance Related Indicator to Predict the Survival of Patients with Cancer. Frontiers in Endocrinology. 2022;13:905266.
Author contributions:
Yanina A.V. – development of the research concept and design, collection and analysis of literature, drafting of the manuscript. Godilo-Godlevsky V.A. – development of the research concept and design, data analysis, drafting and scientific editing of the manuscript. Gornov S.V. – development of the theoretical framework, development and modification of research methods, statistical data processing, scientific editing of the manuscript. Reznik E.V. – development of the research concept and design, drafting of the manuscript, approval of the final version of the article.
Conflict of interest. The authors declare no conflict of interest.
Financing. The study had no sponsorship.
Article received: 20.05.2026. Accepted for publication: 06.09.2026.